ADVAGEN, a Singapore based company founded in 2006 which develops and markets healthcare supplements and pharmaceuticals, is pleased to announce its chemotherapeutic product, Oxaliplatin ADVAGEN, is now approved in Singapore.

“With the approval of Oxaliplatin, we are glad to be able to expand our range of therapeutic products in Singapore and will continue to strive to provide safe, effective, and affordable treatment options for all our patients and healthcare providers.” – Soo, Regulatory Affairs